 |
JOURNAL TOOLS |
| Opzioni di pubblicazione |
| eTOC |
| Per abbonarsi |
| Sottometti un articolo |
| Segnala alla tua biblioteca |
ARTICLE TOOLS |
| Estratti |
| Permessi |
| Share |
I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
CASI CLINICI
Minerva Pneumologica 2014 March;53(1):43-5
Copyright © 2014 EDIZIONI MINERVA MEDICA
lingua: Inglese
Hepatotoxicity due to montelukast: a case-based review of literature
Sargin G. 1, Coskun A. 2, Yavasoglu I. 3, Yasa M. H. 2
1 Department of Internal Medicine Adnan Menderes University Medical Faculty Aydin, Turkey; 2 Division of Gastroenterology Adnan Menderes University Medical Faculty Aydin, Turkey; 3 Division of Hematology Adnan Menderes University Medical Faculty Aydın, Turkey
Montelukast is a selective antagonist of cysteinyl leukotriene receptors. Drug-induced hepatotoxicity and abnormal levels of serum aminotransferases may be detected in patients without any clinical symptoms. In literature, several side effects about montelukast have been reported with clinical sings such as jaundice etc. with elevated bilirubin levels. Here, we report 60-year-old female patient who had a medical history about montelukast receiving and elevated serum aminotransferases without any clinical sings.